Halobetasol propionate is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. It is available as ointment, cream and lotion for topical use. MedsAcross supplies Halobetasol propionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Halobetasol Propionate Lotion 0.05% is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Halobetasol Propionate Lotion 0.05% is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.
Source: US FDA prescribing information
Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, however, the precise mechanism of action in plaque psoriasis is unknown.
Source: US FDA prescribing information
Apply a thin layer of Halobetasol Propionate Lotion 0.05% to the affected skin twice daily for up to two weeks. Rub in gently. Discontinue therapy when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Treatment beyond two weeks is not recommended and the total dosage should not exceed 50 grams (50 ml) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis {see Warnings and Precautions 5.1 ].Do not use with occlusive dressings unless directed by a physician. Halobetasol Propionate Lotion 0.05% is for external use only. Avoid use on the face, scalp, groin, or axillae. Halobetasol Propionate Lotion 0.05% is not for ophthalmic, oral, or intravaginal use. Apply a thin layer to the affected areas twice daily. Limit use to 50 g/week. Discontinue treatment when control is achieved.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
- Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic absorption may require evaluation for HPA axis suppression. Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical corticosteroids. Local adverse reactions with topical steroids may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis. Adverse reactions may be more likely to occur with occlusive use or more potent corticosteroids.
Source: US FDA prescribing information
- The most commonly reported adverse reactions (≥1%) are telangiectasia, application site atrophy, and headache. See 17 for PATIENT CONSELING INFORMATION Revised: 03/2026
Source: US FDA prescribing information
Store at 25'C (77'F), excursions permitted to 15°G and 30°G (59° F to 86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Halobetasol propionate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Halobetasol propionate 0.05% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Halobetasol propionate 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Bryhali 0.01% lotionTopical | Bausch Health | US FDA | Available on request |
| Halobetasol propionate 0.05% lotionTopicalGeneric name | — | US FDA | Available on request |
| Halobetasol propionate 0.05% foamTopicalGeneric name | — | US FDA | Available on request |
| Lexette 0.05% foamTopical | Mayne Pharma | US FDA | Available on request |
| Ultravate 0.05% lotionTopical | Lacer Pharma | US FDA | Available on request |
3 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 17 December 1990 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 7 presentations of Halobetasol propionate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Halobetasol propionate, including Bryhali, Lexette, Ultravate.
Yes. The US FDA first approved Halobetasol propionate on 17 December 1990, according to Drugs@FDA.
No listed presentation of Halobetasol propionate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Halobetasol propionate is classified under ATC code D07AC21 (Halobetasol propionate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.